Evidence map›Paper›PMID 37031487›Full record

ArticleDrug and alcohol dependence2023

Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.

Lakshmi Ganapathi, Allison M McFall, Kimberly F Greco, Aylur K Srikrishnan, Muniratnam Suresh Kumar, Kenneth H Mayer, Conall O'Cleirigh, Shruti H Mehta, Gregory M Lucas, Sunil S Solomon

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Lakshmi GanapathiDivision of Pediatric Global Health, Massachusetts General Hospital for Children, 55 Fruit Street, Boston, MA 02114, USA; Division of Pediatric Infectious Diseases, Massachusetts General Hospital for Children, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: lganapathi@mgh.harvard.edu.
Allison M McFallDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, 733 N Broadway, Baltimore, MD 21205, USA.
Kimberly F GrecoInstitutional Centers for Clinical and Translational Research, Boston Children's Hospital, 21 Autumn Street, Boston, MA 02215, USA.
Aylur K SrikrishnanYR Gaitonde Centre for AIDS Research and Education, No. 34, East Street, Kilpauk Garden Colony, Chennai 600010, India.
Muniratnam Suresh KumarYR Gaitonde Centre for AIDS Research and Education, No. 34, East Street, Kilpauk Garden Colony, Chennai 600010, India.
Kenneth H MayerHarvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA; The Fenway Institute, 1340 Boylston Street, Boston, MA 02215, USA.
Conall O'CleirighHarvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Shruti H MehtaDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, 733 N Broadway, Baltimore, MD 21205, USA.
Gregory M LucasDivision of Infectious Diseases, The Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
Sunil S SolomonDivision of Infectious Diseases, The Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
Johns Hopkins University · USBoston Children's Hospital · USYR Gaitonde Centre for AIDS Research and Education · INBeth Israel Deaconess Medical Center · USHarvard University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Strategies to improve the HIV care continuum among key populations in IndiaR01DA041034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2015 to 2021
$6.7M
Integrated Care Clinics for IDUs in India: a cluster randomized trialR01DA032059 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2011 to 2015
$6.3M
Reaching the hardest of the hard-to-reachDP2DA040244 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2023
$2.8M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Yuva Sath (Youth Together): A peer-led intervention to support substance use treatment engagement and HIV prevention among young people who inject drugsK23DA057151 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Lakshmi Ganapathi · 2023 to 2026
$777k
NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIDA NIH HHS DP2 DA040244NIDA NIH HHS K23 DA057151NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA032059NIDA NIH HHS R01 DA041034
6 · The paper itself

Abstract

backgroundIndia is facing overlapping opioid injection and HIV epidemics among people who inject drugs (PWID) in several cities. Integrated Care Centers (ICCs) provide single-venue HIV and substance use services to PWID. We evaluated PWID engagement in daily observed buprenorphine treatment at 7 ICCs to inform interventions.

methodsWe analyzed 1-year follow-up data for PWID initiating buprenorphine between 1 January - 31 December 2018, evaluating receipt frequency, treatment interruptions (no buprenorphine receipt for 60 consecutive days with subsequent re-engagement), and drop-out (no buprenorphine receipt for 60 consecutive days without re-engagement). Using descriptive statistics, we explored differences between ICCs in the opioid-endemic Northeast region and ICCs in the emerging opioid epidemic North/Central region. We used a multivariable logistic regression model to determine predictors of treatment drop-out by 6 months.

results1312 PWID initiated buprenorphine (76% North/Central ICCs vs. 24% Northeast ICCs). 31% of PWID in North/Central, and 25% in Northeast ICCs experienced ≥ 1 treatment interruption in 1 year. Over 6 months, 48% of PWID in North/Central vs. 60% in Northeast ICCs received buprenorphine ≤ 2 times/week (p < 0.0001). A third of PWID in North/Central vs. half in Northeast ICCs experienced treatment drop-out by 6 months (p < 0.001). In the multivariable model, living in Northeast cities was associated with increased odds of drop-out while counseling receipt was associated with decreased odds.

conclusionsRetention among PWID initiating buprenorphine at ICCs was comparable to global reports. However, regional heterogeneity in retention, and low daily buprenorphine receipt suggest patient-centered interventions adapted to regional contexts are urgently needed.

Indexed as

BuprenorphineDelivery of Health Care, IntegratedDrug UsersHIV InfectionsSubstance Abuse, IntravenousAnalgesics, OpioidHumansAnalgesics, OpioidBuprenorphineBuprenorphineIndiaOpioid usePeople who inject drugsRetentionTreatment

Identifiers

PMID37031487
PMCPMC10416117
OpenAlexW4327919021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.